Kory James Wentworth, Chief Financial Officer at Entrada Therapeutics, Inc. (TRDA), sold 3,110 shares at $18.20 ($57K) on 2022-12-02, disclosed to the SEC on 2022-12-06.
Open-market sale of $57k TRDA by Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $18.20 | 2,910 | $53K | 93.6% |
| 2 | $18.05 | 200 | $4K | 6.4% |
| Total | $18.19 avg | 3,110 | $57K | 100% |
| Filing → |
| TRDA | SELL | 2026-03-06 | $196K | — | Filing → |
| TRDA | SELL | 2025-11-24 | $178K | — | Filing → |
| TRDA | SELL | 2025-03-19 | $19K | — | Filing → |